Ms. Reumuth has served as our Chief Financial Officer since July 2017, Senior Vice President, Finance from February 2017 to July 2017, our Vice President, Finance from December 2014 to February 2017, our Senior Director, Finance from February 2014 to December 2014, as our Corporate Controller from February 2014 to July 2017 and Treasurer since February 2014. Prior to joining us, Ms. Reumuth acted as an independent financial consultant from November 2012 to January 2014 and, prior to that, served as Corporate Controller for Enobia Pharma Corp., or Enobia, a global biopharmaceutical company acquired by Alexion Pharmaceuticals, Inc., from May 2011 to June 2012. Prior to Enobia, Ms. Reumuth served as Director of Finance at Verenium Corporation, or Verenium, a biotechnology company, from December 2007 to March 2011. From 2001 to 2007, Ms. Reumuth held a variety of finance and accounting positions at Genzyme Corporation, or Genzyme, (now a Sanofi Company), and ILEX Oncology, Inc., or ILEX (acquired by Genzyme). Prior to ILEX, Ms. Reumuth was an auditor at Ernst & Young LLP. Ms. Reumuth earned her Bachelor’s degree in Business Administration from Texas A&M University—Corpus Christi, and is a Certified Public Accountant.
How old is Mary Reumuth?
Ms. Reumuth is currently 49 years old. There are 6 older executives and no younger executives at KALA BIO. The oldest executive at KALA BIO is Dr. Kim Brazzell Ph.D., Head of R&D and Chief Medical Officer, who is 71 years old. Learn More on Mary Reumuth's age.
How do I contact Mary Reumuth?
Has Mary Reumuth been buying or selling shares of KALA BIO?
Mary Reumuth has not been actively trading shares of KALA BIO within the last three months. Most recently, Mary Reumuth sold 2,850 shares of the business's stock in a transaction on Tuesday, January 4th. The shares were sold at an average price of $1.30, for a transaction totalling $3,705.00. Learn More on Mary Reumuth's trading history.
Who are KALA BIO's active insiders?
Are insiders buying or selling shares of KALA BIO?
In the last twelve months, insiders at the sold shares 2 times. They sold a total of 5,766 shares worth more than $38,817.45. The most recent insider tranaction occured on January, 4th when insider Eric Trachtenberg sold 1,227 shares worth more than $8,269.98. Insiders at KALA BIO own 13.4% of the company.
Learn More about insider trades at KALA BIO. Information on this page was last updated on 1/4/2024.